Circadian toxicology of cyclosporin

Guido Magnus, Marco Cavallini, Franz Halberg, Germaine Cornelissen, David E R Sutherland, John A. Najarian, William J M Hrushesky

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Cyclosporin (Cs), a cyclic nonpolar undecapeptide of fungal origin, has potent immunosuppressive and antiparasitic activities, and renal and hepatic toxicities, the mechanisms of which are not worked out. Many nephrotoxins and hepatotoxins are predictably more or less harmful, depending upon the circadian stage at which they are administered. In order to find treatment schedules that might damage the animal least, the toxicity of 20 mg kg-1 day-1 of Cs given intraperitoneally was studied at six different circadian stages in adult male Lewis rats. Cs toxicity was gauged by body temperature decline, body weight loss, and survival time. Rectal temperatures over a 24-hr span during the 2 days prior to the first death revealed that rats treated during darkness were 1.6 ± 0.3°C cooler than vehicle-treated controls, whereas rats treated during the light span were only 0.4 ± 0.2°C cooler than controls (p < 0.01). Rats treated in darkness lost twice as much weight compared to those treated in light (20 ± 2 versus 10 ± 2%, p < 0.01). Rats receiving daily Cs in the dark span lived an average of 28 ± 5 days compared with 44 ± 4 days for animals getting Cs during the light span (p < 0.05). Three separate nonspecific measures of drug toxicity confirmed that there was substantial circadian stage dependence to Cs toxicity. The safest time for the drug in rats was 2 to 10 hr after lighting onset, a time when rats are usually beginning their diurnal rest and/or sleep span.

Original languageEnglish (US)
Pages (from-to)181-185
Number of pages5
JournalToxicology and Applied Pharmacology
Issue number1
StatePublished - Jan 1985

Bibliographical note

Funding Information:
This study was supported by Grant GM-13981 from the National Institute of General Medical Sciences, Grant CA-14445 National Cancer Institute, funds from the Minnesota Medical Foundation, Grant ROl CA 31635-02 from the National Cancer Institute, and Grant AM-13083 from the National Institutes of Health.


Dive into the research topics of 'Circadian toxicology of cyclosporin'. Together they form a unique fingerprint.

Cite this